Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report

Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878-882. doi: 10.1161/ATVBAHA.120.315547. Epub 2020 Dec 3.

Abstract

Objective: Patients with coronavirus disease 2019 (COVID-19) have a high rate of thrombosis. We hypothesized that severe acute respiratory syndrome coronavirus 2 infection leads to induction of TF (tissue factor) expression and increased levels of circulating TF-positive extracellular vesicles (EV) that may drive thrombosis. Approach and Results: We measured levels of plasma EV TF activity in 100 patients with COVID-19 with moderate and severe disease and 28 healthy controls. Levels of EV TF activity were significantly higher in patients with COVID-19 compared with controls. In addition, levels of EV TF activity were associated with disease severity and mortality. Finally, levels of EV TF activity correlated with several plasma markers, including D-dimer, which has been shown to be associated with thrombosis in patients with COVID-19.

Conclusions: Our results indicate that severe acute respiratory syndrome coronavirus 2 infection induces the release of TF-positive EVs into the circulation that are likely to contribute to thrombosis in patients with COVID-19. EV TF activity was also associated with severity and mortality.

Keywords: COVID-19; coronavirus; extracellular vesicles; fibrinogen; thrombosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • COVID-19 / blood*
  • COVID-19 / complications*
  • COVID-19 / mortality
  • Extracellular Vesicles / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Severity of Illness Index
  • Thrombosis / prevention & control
  • Thrombosis / virology

Substances

  • Anticoagulants